GRM2 and depressive symptom measurement: A better understanding of the nature of interactions between mGlu2/3 receptors and hallucinogenic substances can provide potential molecular mechanisms related to complex processes in the brain and thus contribute to the development of safer, more effective, so-called new-age pharmacotherapies for depression.